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Abstract: The convenient, metal-free reduction of imines that
contain an inexpensive and removable chiral auxiliary allowed
for the synthesis of the immediate precursors of chiral active
pharmaceutical ingredients (APIs). This protocol was carried out
under batch and flow conditions to give the correspoding prod-
ucts in high yields with almost complete stereocontrol. In the
presence of trichlorosilane, an inexpensive and nontoxic reduc-
ing agent, and an achiral Lewis base such as N,N-dimethyl-
Introduction
The pharmaceutical industry is gradually progressing towards
enantiopure formulations. Most newly introduced drugs are
chiral, and it is expected that approximately 95 % of pharma-
ceutical drugs will be chiral by 2020.[1] In this context, chiral
amines are considered a class of paramount importance, be-
cause they are found in a plethora of compounds such as those
of pharmaceutical interest as well as those developed for agro-
chemicals, fragrances, and fine chemicals.[2] The reduction of
the C=N group is one of the most widely used approaches to
synthesize chiral amines, and over the last ten years, successful
catalytic enantioselective methods based on both metal-pro-
moted[3] and organocatalyzed[4] strategies have been devel-
oped.
When an industrial synthesis of a chiral pharmaceutical prod-
uct must be planned, however, issues such as the chemical effi-
ciency and robustness of the procedure, its general applicabil-
ity, and economic considerations become crucially important.
For these reasons, the applications of many chiral catalytic sys-
tems are often not feasible, and the use of inexpensive and
readily available chiral auxiliaries becomes an attractive and
economic alternative. This also holds true for the synthesis of
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formamide, the formal syntheses of Rivastgmine, calcimimetic
NPS R-568, and a Rho kinases inhibitor were successfully accom-
plished. For the first time, both the diastereoselective imine re-
duction and the auxiliary removal were efficiently performed in
a micro- or mesoreactor under continuous-flow conditions,
which paved the way towards the development of a practical
process for the syntheses of industrially relevant, biologically
active, enantiopure N-alkylamines.
chiral amines[5] that rely heavily on the diastereoselective re-
duction of N-functionalized imines that contain removable chi-
ral auxiliaries.[6] Taking these details into consideration, we pro-
ceeded to investigate an efficient synthesis for both enantio-
mers of 1-(m-hydroxyphenyl)ethylamine, a key intermediate in
the preparation of several valuable pharmaceutically active
compounds (Scheme 1).
Rivastgmine finds application in the treatment of mild to
moderate dementia resulting from types of Alzheimer's and Par-
kinson diseases. Miotine, the first synthetic carbamate used clin-
ically, is an anticholinesterase drug. Rho-associated protein kin-
ase (ROCK) inhibitors have proved to be efficacious in animal
models of stroke, inflammatory diseases, Alzheimer's disease,
and neuropathic pain, and, therefore, have the potential to pre-
vent the neurodegeneration and simulated neurodegeneration
of various neurological disorders. (R)-NPS 568 is a calcimimetic
compound that is used in the treatment of hyperparathyroid-
ism, whereas acrylamide (S)-A, a potent KCNQ2 opener, is cur-
rently under study for the treatment of neuropathic pain, in-
cluding diabetic neuropathy. The importance of chiral N-alkyl-
amines in medicinal chemistry, which encompasses a large vari-
ety of compounds with differing biological activities, has been
recently highlighted.[7]
Our goal was not only to develop an efficient, metal-free
reduction of imines that contain an inexpensive and easily re-
movable chiral auxiliary but also to achieve the transformation
under continuous-flow conditions.[8] Herein we report a tri-
chlorosilane-mediated C=N reduction efficiently performed in a
micro- or mesoreactor followed by N-deprotection under flow
conditions in a microfluidic device to afford both enantiomers
of essentially pure 1-(m-alkoxyaryl)ethylamine derivatives,
which are advanced precursors of several valuable active phar-
maceutical ingredients (APIs).[9]
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Scheme 1. Biologically active amines featuring the 1-(m-alkoxyphenyl)ethylamine moiety.
Results and Discussion
Our investigation began with the reduction of N-[1-(R)-phenyl-
ethyl]ethan-1-[3-(methoxy)phenyl]-1-imine (1) under batch con-
ditions,[10] which was successfully accomplished by using
3.5 mol-equiv. of trichlorosilane in the presence of 5 mol-equiv.
of N,N-dimethylformamide (DMF) in dry dichloromethane
(DCM) for 18 h (Scheme 2). The corresponding amine 2, which
was isolated in 95 % yield as a single isomer,[11] was subjected
Scheme 2. Synthesis of (R)-1-(3-methoxyphenyl)ethylamine (3), the direct precursor of (R)-NPS 568.
Scheme 3. Under batch conditions, the synthesis of (S)-1-(3-hydroxyphenyl)ethylamine (6) and amine 8, immediate precursors of rivastgmine and analogous
derivatives.
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to a Pd/C-catalyzed hydrogenolysis in ethanol to afford enantio-
merically pure (R)-1-(3-methoxyphenyl)ethylamine (3) in quanti-
tative yield, the direct precursor of calcimimetic (R)-NPS 568.
Similarly, the reduction of 3-benzyl-protected imine 4 was
achieved in high yield and with complete stereocontrol at
–20 °C in DCM (Scheme 3). A series of experiments showed that
it was possible to reduce the reaction time from 18 to 6 h
without an appreciable change to the yield or stereoselectivity
(Table 1, Entry 5). Additionally, we performed the transforma-
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tion in toluene and anisole, both eco-friendly solvents,[12] and
good product yields (e.g., 77 %) with high stereoselectivities
(96:4 with anisole) were observed.
Table 1. Reduction of benzyl-protected chiral imine 4 under batch conditions.
Entry T [°C] DMF [equiv.] Solvent Yield [%][a] dr[b]
1 0 10 DCM 85 92:8
2 –20 10 DCM 81 >98:2
3 0 5 DCM 91 92:8
4 –20 5 DCM 90 97:3
5[c] –20 5 DCM 83 97:3
6 –20 5 toluene 67 92:8
7 –20 5 anisole 77 96:4
[a] Isolated yields are provided. The reaction time was 18 h. [b] Determined
by 1H NMR spectroscopy. [c] Reaction time was 6 h.
The trichlorosilane-mediated reduction of chiral imine 7,
which features a carbamate group on the aromatic ring, was
also effective and led to the isolation of chiral N-methylamine
8, an immediate precursor to (S)-rivastgmine, in 81 % yield as a
single isomer [>98:2 diastereomeric ratio (dr)].[13] To the best of
our knowledge, this is the first example of a stereoselective
reduction of this class of imines under mild conditions without
any degradation of the carbamate moiety.
In the attempt to realize the one-step double deprotection
of amine 5, a hydrogenolysis reaction was performed under the
previously reported conditions to give (S)-1-(3-hydroxy-
phenyl)ethylamine (6) in 83 % yield as a pure enantiomer after
chromatographic purification. This chiral amine represents a key
intermediate in the syntheses of rivastgmine, miotine, and the
KCNQ2 opener acrylamide (S)-A, whereas its enantiomer is the
immediate precursor of a very promising class of Rho-kinases
inhibitors (Scheme 1).
Once the chemistry under batch conditions was successfully
developed, we turned our attention to examine a continuous-
flow process.[14] The safe manufacturing of organic (i.e., chiral)
Scheme 4. Continuous-flow reduction of chiral imines and removal of the chiral auxiliary by continuous-flow hydrogenation to afford pure primary amines.
Table 2. Reduction of chiral imines 1, 4, and 7 under continuous-flow conditions.
Entry R Imine T [°C] Flow rate [μL min–1] Residence time [min] Yield [%][a] dr[b]
1 Bn 4 15 50 5 70 90:10
2 Bn 4 0 50 5 57 96:4
3 Bn 4 0 25 10 83 93:7
4 Bn 4 –20 25 10 81 98:2
5[c] Bn 4 0 25 10 75 96:4
6 Me 1 –20 25 10 82 95:5
7 CONMeEt 7 –20 25 10 80 98:2
[a] Yields are averages of five different samples collected at different times. The concentrations of the reactions were 0.1 M. [b] Determined by 1H NMR
spectroscopy. [c] Reaction concentration was 0.5 M.
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intermediates under continuous-flow conditions and, more in
general, all of the advantages that continuous processing may
offer are emerging topics that can have a significant impact
on the synthesis of APIs.[15] Therefore, the development of a
continuous-flow process for the preparation of both enantio-
mers of 1-(m-alkoxyphenyl)ethylamine derivatives is an attract-
ive option. As far as we know, there are no reports of continu-
ous-flow processes for the synthesis of these valuable inter-
mediates and no examples of in-flow stereoselective reductions
of imines that use HSiCl3 as a reducing agent.
A coil reactor, realized by using polytetrafluoroethylene
(PTFE) tubing (1.58 mm outer diameter, 0.58 mm inner diame-
ter, 1.89 m length, 500 μL effective volume) coiled in a bundle
and immersed in a bath cooled to the desired temperature, was
employed for our preliminary studies (Scheme 4, see Support-
ing Information for figures and further experimental details).
The continuous-flow reduction of Bn-protected imine 4 was
carried out in DCM at 15 °C with a short residence time (5 min)
to give a good 70 % yield of the product but with a low dia-
stereomeric ratio (90:10; Table 2, Entry 1). As expected, better
results were achieved at 0 °C with a residence time of 10 min,
which provided an 83 % yield of the product with 93:7 dr
(Table 2, Entry 3). At –20 °C, the continuous-flow reduction af-
forded amine 5 in 81 % yield with almost complete stereoselec-
tion (Table 2, Entry 4). Increasing the concentration of the re-
duction reaction from 0.1 to 0.5 M gave comparable yields and
stereoselectivity, which thus demonstrates the possibility to fur-
ther reduce the solvent volumes and attain a more sustainable
process (Table 2, Entry 5).
With the optimal conditions at hand, the reductions of MeO-
functionalized ketoimine 1 and chiral imine 7, a direct precursor
of rivastigmine, were also investigated. Excellent chemical yields
as well as stereoselectivities were obtained in both cases
(Table 2, Entries 6 and 7).
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Scheme 5. Continuous-flow deprotection of amines 2 and 5 to afford chiral primary amines.
The continuous hydrogenolysis[16] of the chiral amines was
then performed with a ThalesNano H-Cube Mini™ that was
equipped with a 10 % Pd/C cartridge. First, the reaction of chiral
amine 2 [Scheme 5, Equation (a)] was examined at 50 °C and a
pressure of 50 bar, but no conversion was observed, and the
starting material was recovered from the reaction mixture
(Table 3, Entry 1). By increasing the temperature to 80 °C and
the pressure to 80 bar, chiral amine 3 was isolated in 70 % yield
(Table 3, Entry 2). A further increase in temperature and pres-
sure had no appreciable effect, but with the additional increase
in the reaction time, an 80 % conversion was obtained (Table 3,
Entry 4). To avoid too harsh conditions and to increase the yield,
we decided to perform the reaction over a longer period of
time by using a closed-loop system. After 2 h at 80 °C and a
pressure of 80 bar, the reaction gave an isolated product yield
of 95 % (Table 3, Entry 5), but carrying out the reaction at 70 °C
and a pressure of 70 bar required 6 h to achieve a 93 % yield
without any appreciable epimerization at the benzylic stereo-
center of the product (Table 3, Entry 6).
Table 3. Continuous-flow hydrogenolysis reaction of chiral amines 2 and 5.
Entry Amine T Flow rate Pressure Reaction time Yield[a]
[°C] [mL min–1] [bar] [min] [%]
1 2 50 1 50 10 n.r.
2 2 80 1 80 10 70
3 2 95 0.5 95 20 70
4 2 95 0.3 95 23 80
5[b] 2 80 1 80 120 95
6[b] 2 70 1 70 360 93
7[b] 5 90 1 80 120 90[c]
8[b] 5 80 1 80 240 70
9[b] 5 80 1 80 360 85
[a] Isolated yields are provided. The concentrations of the reactions were
0.1 M. n.r. = no reaction. [b] Reactions were run by using a closed-loop sys-
tem. [c] Product 9 was obtained in 90 % yield as the major product.
With the reaction conditions in hand, we then explored the
removal of the chiral auxiliary in amine 5. After 2 h at 90 °C,
the deprotection of amine 5 occurred to give O-debenzylated
product 9 in 90 % yield (Table 3, Entry 7). After the reaction
had proceeded at 80 °C for 4 h, the desired chiral amine 6 was
isolated in 70 % yield, which was further increased to 85 % yield
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by running the hydrogenolysis reaction under continuous-flow
conditions for 6 h (Table 3, Entries 8 and 9).
Conclusions
We have developed an efficient protocol for the synthesis of
both enantiomers of 1-(m-hydroxyphenyl)ethylamine, a key in-
termediate in the preparation of several valuable pharmaceuti-
cally active compounds. For the first time, stereoselective tri-
chlorosilane-mediated reduction reactions were successfully
performed in a mesoreactor followed by continuous flow
hydrogenolysis reactions to afford enantiomerically pure 1-(3-
alkoxyphenyl)ethylamines in good yields in short reaction times
and reduced solvent volumes. The development of a highly effi-
cient “all flow” multistep, sequential procedure that starts from
a ketone and includes the reductive amination and deprotec-
tion steps to afford enantiomerically pure pharmaceutically rel-
evant amines is currently under investigation.
Experimental Section
General Procedure for the Reduction of Imines with HSiCl3 un-
der Batch Conditions: Dry DMF (5 equiv.) and a 0.9 M solution of
the imine in dry solvent were added to a 10 mL round-bottom flask
under N2 and further diluted with dry solvent (2 mL). The mixture
was cooled to the desired reaction temperature. A 1.6 M solution of
HSiCl3 (0.7 mmol, 3.5 equiv.) in the selected solvent was added to
the reaction mixture. After the desired time, the reaction was
quenched with NaOH (0.1 M solution) until a basic pH was reached.
The resulting slurry was stirred at room temperature for 10 min,
and then Na2SO4 was added as a drying agent. The mixture was
filtered through a pad of Celite, and the filter cake was washed with
CH2Cl2 (10 mL) and ethyl acetate (10 mL). The solvent was removed
under reduced pressure, and the diastereomeric ratio of the crude
mixture was determined. The amines were purified by flash chroma-
tography on silica gel or by crystallization.
General Procedures for the Reduction of Imines with HSiCl3 un-
der Continuous-Flow Conditions: At the desired temperature, the
500 μL coil reactor was fed by using two 2.5 mL Hamilton gastight
syringes at the desired flow rate. Syringe A was filled with a solution
of the imine (1 mol-equiv.) and dry DMF (5 mol-equiv.) in dry DCM.
Communication
Syringe B was filled with a solution of HSiCl3 in DCM. The concentra-
tions of the reagents in the syringes were set according to the
desired concentration in the reactor. The reaction mixture was col-
lected in a round-bottom flask, which was filled with NaOH (0.1 M
solution) at the same reaction temperature. After the first amount
was discharged, the steady-state conditions were reached. The re-
ported yields are given as an average of five different samples col-
lected at different times.
General Procedure for Deprotection of Amine under Batch Con-
ditions: To a 0.5 M solution of the amine in ethanol in a vial for
high-pressure hydrogenation (Parr instrument) was added 10 % of
Pd/C, and the hydrogenation was carried out at 10 bar for 48 h.
Compound 3: The general procedure above was employed. The
resulting ethanol suspension was filtered through a pad of Celite,
and the filter cake was washed with MeOH (50 mL). The filtrate was
then treated with HCl (2 M in Et2O, 1 equiv.). The solvents were
removed under reduced pressure, and the resulting residue was
dissolved in DCM. The solution was treated with Amberlyst IRA-400
(OH–) resin to isolate the amine as a neutral compound.
Compound 6: The general procedure above was employed. The
resulting ethanol suspension was filtered through a pad of Celite,
and the filter cake was washed with MeOH (50 mL). The filtrate was
concentrated under reduced pressure to give the compound as a
neutral amine.
General Procedure for H-Cube Mini Deprotection of Amine.
Preparation of (1S)-(3-Hydroxyphenyl)ethanamine (6): A 0.1 M
solution of the amine (0.5 g, 1.51 mmol) in ethanol (15 mL) was
added to a vial connected to the pump of the H-CUBE Mini, which
was equipped with a 30 mm cartridge of 10 % Pd/C. The instrument
was previously stabilized at the desired temperature and pressure
and at a flow rate of 1 mL min–1. The reaction was run in a close-
loop system for the desired time. 1H NMR (300 MHz, CD3OD): δ =
7.19 (t, J = 8.1 Hz, 1 H), 6.91–6.81 (m, 2 H), 6.82–6.72 (m, 1 H),
4.27–4.13 (m, 1 H), 1.51 (d, J = 6.8 Hz, 3 H) ppm.
[α]D25 = –22.1 (c = 1, methanol). The spectroscopic data and the
optical rotation are in agreement with those in the literature.[17]
GC method [(injector: 200 °C; flow rate: 2 mL min–1; temperature:
program 100 °C (hold 2 min), 130 °C at a rate of 1 °C min–1 (hold
5 min); 170 °C at a rate of 2 °C min–1 (hold 5 min)]: tR = 58.219 min.
Supporting Information (see footnote on the first page of this
article): Synthesis of starting materials (ketones and ketoimines);
synthesis of chiral amines 2, 3, 5, 6, and 8; detailed experimental
procedures for the reduction and hydrogenolysis procedures; and
characterization data of compounds.
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